Literature DB >> 29174576

DNA binding and Topoisomerase inhibition: How can these mechanisms be explored to design more specific anticancer agents?

Sinara Mônica Vitalino de Almeida1, Amélia Galdino Ribeiro2, Geilza Carla de Lima Silva3, Josival Emanuel Ferreira Alves3, Eduardo Isidoro Carneiro Beltrão3, Jamerson Ferreira de Oliveira2, Luiz Bezerra de Carvalho3, Maria do Carmo Alves de Lima4.   

Abstract

DNA is considered one of the most promising targets of molecules with anticancer activity potential. Its key role in various cell division mechanisms, which commands the intense multiplication of tumor cells, is considered in studies with compounds whose mechanisms of action suggest likeliness of interaction. In addition, inhibition of enzymes that actively participate in biological functions of cells such as Topoisomerase, is seen as a primary factor for conducting several events that result in cell death. Discovery of new anticancer chemotherapeutical capable of interacting with DNA and inhibiting Topoisomerase enzymes is highlighted in anticancer research. The present review aims at showing through distinct biological tests the performance of different candidates to anticancer drugs and their respective chemical modifications, which are crucial and/or determinant for DNA affinity and inhibition of important enzymes in cells' vital processe to either separately or synergistically optimize anticancer activity.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Acridine derivatives; DNA-topoisomerase; Metallic compounds; Nitrogenous heterocyclic derivatives; Thiosemicarbazone

Mesh:

Substances:

Year:  2017        PMID: 29174576     DOI: 10.1016/j.biopha.2017.11.054

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Apoptotic and antioxidant effects in HCT-116 colorectal carcinoma cells by a spiro-acridine compound, AMTAC-06.

Authors:  Sâmia Sousa Duarte; Daiana Karla Frade Silva; Thaís Mangeon Honorato Lisboa; Rawny Galdino Gouveia; Camyla Caroliny Neves de Andrade; Valgrícia Matias de Sousa; Rafael Carlos Ferreira; Ricardo Olimpio de Moura; Joilly Nilce Santana Gomes; Patricia Mirella da Silva; Fátima de Lourdes Assunção Araújo de Azevedo; Tatjana S L Keesen; Juan Carlos Ramos Gonçalves; Leônia Maria Batista; Marianna Vieira Sobral
Journal:  Pharmacol Rep       Date:  2022-03-17       Impact factor: 3.024

2.  Acridine Based N-Acylhydrazone Derivatives as Potential Anticancer Agents: Synthesis, Characterization and ctDNA/HSA Spectroscopic Binding Properties.

Authors:  Mária Vilková; Monika Hudáčová; Nikola Palušeková; Rastislav Jendželovský; Miroslav Almáši; Tibor Béres; Peter Fedoročko; Mária Kožurková
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

3.  Topoisomerases inhibition and DNA binding mode of daunomycin-oligoarginine conjugate.

Authors:  Valeria Visone; Ildikó Szabó; Giuseppe Perugino; Ferenc Hudecz; Zoltán Bánóczi; Anna Valenti
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

4.  Photo-activated proflavine degrades protein and impairs enzyme activity: Involvement of hydroxyl radicals.

Authors:  Mansour K Ghatasheh; Abdul Malik; Mohammad Shamsul Ola; Abdullah S Alhomida
Journal:  Toxicol Rep       Date:  2021-12-21

Review 5.  DNA topoisomerases as molecular targets for anticancer drugs.

Authors:  Kamila Buzun; Anna Bielawska; Krzysztof Bielawski; Agnieszka Gornowicz
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.